Oncologic and functional outcomes after laparoscopic radical prostatectomy:10-years follow-up

doi:10.3969/j.issn.1006-7795.2023.03.011

Abstract

Abstract: Objective To assess long-term urinary control function, sexual function and disease recurrence, overall mortality, and risk of death from prostate cancer after laparoscopic radical prostatectomy(LRP). Methods Oncologic outcomes and functional outcomes were analyzed retrospectively in 99 patients who underwent LRP from June 2009 to December 2013. Finally 80 patients were included in the study according to the exclusion criteria. Cox regression was used to analyze the risk factors for overall survival(OS), cancer-specific survival(CSS), and radiologic progression-free survival(rPFS) after LRP. Results The 5-year and 10-year OS rates after LRP were 86% and 70%, the CSS rates were 91% and 85%, and PFS rates were 87% and 76%, respectively. Pathological Gleason score and failure to achieve clinical cure after surgery were independent risk factors for OS, pathological Gleason score was an independent risk factor for CSS, and the highest preoperative prostate specific antigen (PSA) level > 20 ng/mL was an independent risk factor for PFS, but failure to achieve clinical cure after surgery had a marginal significance on CSS and PFS. The rate of urinary continence was 76.8%, 21.4% had urinary incontinence to varing degree, 51.8% had no sexual stimulation or arousal, 12.5% had normal sexual activity, and 35.7% had erectile dysfunction insufficient to maintain normal sexual activity, and the incidence of erectile dysfunction was higher in patients without preserving vascular nerve bundles than those with preservation during LRP. Conclusion The 10-year long-term outcomes of oncology and urinary continence after LRP are similar to the previous reports, LRP is an optimal option to achieve satisfactory oncological and functional outcomes for patients with prostate cancer.

Key words: laparoscopic radical prostatectomy, oncologic and functional outcomes, clinical cure, urinary incontinence, erectile dysfunction

CLC Number:

R737.25

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2023.03.011

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2023/V44/I3/424

References

［1］Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin, 2021, 71(3): 209－249.
［2］Siegel R L, Miller K D, Fuchs H E, et al. Cancer statistics, 2022［J］. CA Cancer J Clin, 2022, 72(1): 7－33.
［3］Nouhi M, Mousavi S M, Olyaeemanesh A, et al. Long-term clinical outcomes of radical prostatectomy versus watchful waiting in localized prostate cancer patients: a systematic review and meta-analysis［J］. Iran J Public Health, 2019, 48(4): 566－578.
［4］Lantz A, Bock D, Akre O, et al. Functional and oncological outcomes after open versus robot-assisted laparoscopic radical prostatectomy for localised prostate cancer: 8-year follow-up［J］. Eur Urol, 2021, 80(5): 650－660.
［5］Moreira D M, Presti J C, Jr, Aronson W J, et al. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases［J］. Int J Urol, 2010, 17(11): 914－922.
［6］García Cortés , Colombás Vives J, Gutiérrez Castaé C, et al. Comparison of surgical approaches to radical prostatectomy in our series beyond oncological and functional outcomes［J］. Actas Urol Esp (Engl Ed), 2022, 46(5): 275－284.
［7］Brassetti A, Bollens R. Laparoscopic radical prostatectomy in 2018: 20 years of worldwide experiences, experimentations, researches and refinements［J］. Minerva Chir, 2019, 74(1): 37－53.
［8］Hruza M, Bermejo J L, Flinspach B, et al. Long-term oncological outcomes after laparoscopic radical prostatectomy［J］. BJU Int, 2013, 111(2): 271－280.
［9］Busch J, Stephan C, Herold A, et al. Long-term oncological and continence outcomes after laparoscopic radical prostatectomy: a single-centre experience［J］. BJU Int, 2012, 110(11 Pt C): E985-E990.
［10］Freedland S J, Partin A W, Humphreys E B, et al. Radical prostatectomy for clinical stage T3a disease［J］. Cancer, 2007, 109(7): 1273－1278.
［11］高新, 江东根, 黄群雄, 等. 根治性前列腺切除联合扩大盆腔淋巴结清扫术治疗局部高危前列腺癌12年经验总结［J］. 中华泌尿外科杂志, 2017, 38(6): 433－437.
［12］王喻, 孙卓伦, 李腾成, 等. 扩大盆腔淋巴结清扫+前列腺癌根治术治疗局部高危前列腺癌十年随访结果［J］. 中华腔镜泌尿外科杂志: 电子版, 2022, 16(2): 101－105.
［13］Sakai I, Harada K I, Kurahashi T, et al. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer［J］. Urol Int, 2006, 76(3): 227－231.
［14］Nakamura M, Hasumi H, Miyoshi Y, et al. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy［J］. Int J Urol, 2005, 12(12): 1050－1054.
［15］Moreira D M, Presti J C, Jr, Aronson W J, et al. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database［J］. BJU Int, 2010, 105(11): 1541－1547.
［16］Ghabili K, Park H S, Yu J B, et al. National trends in the management of patients with positive surgical margins at radical prostatectomy［J］. World J Urol, 2021, 39(4): 1141－1151.
［17］Rassweiler J, Stolzenburg J, Sulser T, et al. Laparoscopic radical prostatectomy—the experience of the German Laparoscopic Working Group［J］. Eur Urol, 2006, 49(1): 113－119.
［18］Coelho R F, Rocco B, Patel M B, et al. Retropubic, laparoscopic, and robot-assisted radical prostatectomy: a critical review of outcomes reported by high-volume centers［J］. J Endourol, 2010, 24(12): 2003－2015.
［19］Salter C A, Tin A L, Bernie H L, et al. Predictors of worsening erectile function in men with functional erections early after radical prostatectomy［J］. J Sex Med, 2022, 19(12): 1790－1796.

[1]	Zhu Guangyi, Wang Runjin, Xiong Tianyu, Ye Xiaobo, Liu Zhanliang, Cao Fang, Lin Zhemin, Niu Yinong. Analysis of risk factors for second primary malignancies after radical prostatectomy for non-metastatic prostate cancer [J]. Journal of Capital Medical University, 2023, 44(3): 433-438.
[2]	Xiong Tianyu, Niu Yinong. Mechanism of periprostatic adipose tissue affecting the development of prostate cancer [J]. Journal of Capital Medical University, 2023, 44(3): 457-462.
[3]	Jiang Mingxin, Su Yao, Xiong Tianyu, Ye Xiaobo, Jin Song, Xing Nianzeng, Jin Mulan, Yang Mingfu, Niu Yinong. The outcome of cytoreductive radical prostatectomy for prostate cancer patients with bone metastasis [J]. Journal of Capital Medical University, 2021, 42(6): 967-972.
[4]	Wang Mingshuai, Xiong Tianyu, Jiang Mingxin, Qian Xiaosong, Wang Sihao, Cui Yun, Niu Yinong. The effect of modified apical dissection and periurethral structure preservation in the immediate continence recovery after laparoscopic radical prostatectomy [J]. Journal of Capital Medical University, 2021, 42(6): 973-977.
[5]	Ye Xiaobo, Xiong Tianyu, Cui Yun, Wang Mingshuai, Yang Hui, An Zhuoling, Niu Yinong. Efficacy of abiraterone acetate combined with prednisone in the treatment of castration-resistant prostate cancer [J]. Journal of Capital Medical University, 2021, 42(6): 978-985.
[6]	Fan Xiaoqi, Liu Zhibin, Wang Mingshuai, Wasilijiang·Wahafu, Song Liming, Xing Nianzeng, Niu Yinong. Comparative analysis of the improvement of early urinary control after radical prostatectomy by laparoscopic anterior urethral wall reconstruction and "Sandwich" reconstruction [J]. Journal of Capital Medical University, 2020, 41(4): 542-546.
[7]	Xiong Tianyu, Fan Xiaoqi, Niu Yinong. Effects of different modified surgery of radical prostatectomy on urinary continence recovery and erectile function recovery [J]. Journal of Capital Medical University, 2020, 41(4): 558-563.
[8]	Bai Zhijie, Wang Xinsheng, Ma Hongshun, Liu Qian. Clinical study of multiparameter magnetic resonance imaging and ultrasound fusion navigation technology in prostate targeted puncture [J]. Journal of Capital Medical University, 2020, 41(4): 631-635.
[9]	Xie Yingwei, Jin Shipeng, Li Shuang, Wang Yonghui, Wang Wei, Ping Hao, Liu Yuexin. Correlation between TMPRSS2-ERG fusion gene and survival rate of metastatic castration-resistant prostate cancer after chemotherapy [J]. Journal of Capital Medical University, 2020, 41(1): 103-107.
[10]	Ping Hao, Ma Linxiang, Wang Mingshuai, Long Jun, Niu Yinong, Liu Yuexin, Xing Nianzeng. Expression and regulation of monocarboxylate transporters 4(MCT4) in prostate cancer [J]. Journal of Capital Medical University, 2019, 40(1): 59-64.
[11]	Wang Wei, Su Jiaming, Yuan Dongbo, Zhang Wei, Chen Weihong, Sun Zhaolin, Zhu Jianguo. Detection of MAP1A expression in prostate cancer and its clinical characteristics [J]. Journal of Capital Medical University, 2019, 40(1): 65-71.
[12]	Xie Yingwei, Jin Shipeng, Yan Wei, Wang Wei, Ping Hao, Liu Yuexin. Prevalence and prognostic significance of TMPRSS2-ERG fusion gene in prostate cancer with lymph node metastasis [J]. Journal of Capital Medical University, 2019, 40(1): 72-77.
[13]	Zhang Zhiying, Qiu Min, Ma Lulin, Lu Jian. Application of artificial intelligence and 3D image reconstruction in the diagnosis and treatment of prostate cancer [J]. Journal of Capital Medical University, 2019, 40(1): 90-93.
[14]	Wasilijiang Wahafu, Niu Yinong, Xing Nianzeng. Development and future of chemotherapy for prostate cancer [J]. Journal of Capital Medical University, 2016, 37(3): 299-306.
[15]	Sun Jian, Jin Song, Zhao Hongying, Liu Yang, Jin Mulan, Xing Nianzeng, Niu Yinong. Correlation between 5-α reductase and biological behavior of prostate cancer [J]. Journal of Capital Medical University, 2016, 37(3): 307-312.